Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7360, United States.
Mol Pharm. 2011 Oct 3;8(5):1677-86. doi: 10.1021/mp200026v. Epub 2011 Aug 5.
Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp. Evidence exists that multiple uptake and efflux transporters play a role in hepatic disposition of fexofenadine. However, the roles of specific transporters and their interrelationship in intestinal absorption of this drug are unclear. This study was designed to elucidate vectorial absorptive transport of fexofenadine across Caco-2 cells involving specific apical uptake and efflux transporters as well as basolateral efflux transporters. Studies with cellular models expressing single transporters showed that OATP2B1 expression stimulated uptake of fexofenadine at pH 6.0. Apical uptake of fexofenadine into Caco-2 cells was decreased by 45% by pretreatment with estrone 3-sulfate, an OATP inhibitor, at pH 6.0 but not at pH 7.4, indicating that OATP2B1 mediates apical uptake of fexofenadine into these cells. Examination of fexofenadine efflux from preloaded Caco-2 cells in the presence or absence of (i) the MRP inhibitor MK-571 and (ii) the P-gp inhibitor GW918 showed that apical efflux is predominantly mediated by P-gp, with a small contribution by MRP2, whereas basolateral efflux is predominantly mediated by MRP3. These results also showed that while OSTαβ is functionally active in the basolateral membrane of Caco-2 cells, it does not play a role in the export of fexofenadine. MK-571 decreased the absorptive transport of fexofenadine by 17%. However, the decrease in absorptive transport by MK-571 was 42% when P-gp was inhibited by GW918. The results provide a novel insight into a vectorial transport system mainly consisting of apical OATP2B1 and basolateral MRP3 that may play an important role in delivering hydrophilic anionic and zwitterionic drugs such as pravastatin and fexofenadine into systemic circulation upon oral administration.
非镇静抗组胺药地氯雷他定,尽管其化学结构为两性离子,可被 P-糖蛋白外排,但仍具有良好的口服生物利用度。有证据表明,多种摄取和外排转运体在氯雷他定的肝脏处置中发挥作用。然而,特定转运体及其在该药物肠吸收中的相互关系的作用尚不清楚。本研究旨在阐明地氯雷他定在 Caco-2 细胞中的载体吸收转运,涉及特定的顶端摄取和外排转运体以及基底外侧外排转运体。用表达单一转运体的细胞模型进行的研究表明,OATP2B1 的表达在 pH6.0 时刺激地氯雷他定的摄取。在 pH6.0 时,用 OATP 抑制剂雌酮 3-硫酸盐预处理可使地氯雷他定进入 Caco-2 细胞的顶端摄取减少 45%,但在 pH7.4 时则没有,表明 OATP2B1 介导地氯雷他定进入这些细胞的顶端摄取。在存在或不存在(i)MRP 抑制剂 MK-571 和(ii)P-糖蛋白抑制剂 GW918 的情况下,检查预加载 Caco-2 细胞中地氯雷他定的外排,结果表明顶端外排主要由 P-糖蛋白介导,MRP2 也有少量贡献,而基底外侧外排主要由 MRP3 介导。这些结果还表明,虽然 OSTαβ 在 Caco-2 细胞的基底外侧膜中具有功能活性,但它在地氯雷他定的外排中不起作用。MK-571 使地氯雷他定的吸收转运减少了 17%。然而,当 P-糖蛋白被 GW918 抑制时,MK-571 对吸收转运的抑制作用增加到 42%。这些结果为主要由顶端 OATP2B1 和基底外侧 MRP3 组成的载体转运系统提供了新的见解,该系统可能在经口给予亲水阴离子和两性离子药物如普伐他汀和地氯雷他定时,将其递送到全身循环中发挥重要作用。